nach oben

Diabetologia

Erschienen in:

01.01.2011 | Review

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

verfasst von: M. A. Nauck, I. Vardarli, C. F. Deacon, J. J. Holst, J. J. Meier

Erschienen in: Diabetologia | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting postprandial insulin secretion. Since GLP-1 may play a role in the pathophysiology and treatment of type 2 diabetes, assessment of meal-related GLP-1 secretory responses in type 2 diabetic patients vs healthy individuals is of great interest. A common view states that GLP-1 secretion in patients with type 2 diabetes is deficient and that this applies to a lesser degree in individuals with impaired glucose tolerance. Such a deficiency is the rationale for replacing endogenous incretins with GLP-1 receptor agonists or re-normalising active GLP-1 concentrations with dipeptidyl peptidase-4 inhibitors. This review summarises the literature on this topic, including a meta-analysis of published studies on GLP-1 secretion in individuals with and without diabetes after oral glucose and mixed meals. Our analysis does not support the contention of a generalised defect in nutrient-related GLP-1 secretory responses in type 2 diabetes patients. Rather, factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake.

Creutzfeldt W, Nauck M (1992) Gut hormones and diabetes mellitus. Diabetes/Metab Rev 8:149–177CrossRef

Holst JJ, Ørskov C (2001) Incretin hormones—an update. Scand J Clin Lab Invest 234(suppl):75–85

Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705CrossRefPubMed

Meier JJ, Nauck MA (2004) The potential role of glucagon-like peptide 1 in diabetes. Curr Opin Investig Drugs 5:402–410PubMed

Nauck MA, Meier JJ, Creutzfeldt W (2003) Incretins and their analogues as new antidiabetic agents. Drug News Perspect 16:413–422CrossRefPubMed

Nauck MA, Meier JJ (2005) Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes. Regul Pept 124(suppl):135–148CrossRef

Deacon CF, Holst JJ (2006) Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int J Biochem Cell Biol 38:831–844CrossRefPubMed

Åhren B (2007) DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 21:517–533CrossRefPubMed

Holst JJ, Deacon CF (2005) Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48:612–615CrossRefPubMed

10.

Toft-Nielsen MB, Madsbad S, Holst JJ (2001) Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 86:3853–3860CrossRefPubMed

11.

Lugari R, Dei Cas A, Ugolotti D et al (2002) Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res 34:150–154CrossRefPubMed

12.

Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723CrossRefPubMed

13.

Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46–54CrossRefPubMed

14.

Knop FK, Vilsbøll T, Højberg PV et al (2007) Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 56:1951–1959CrossRefPubMed

15.

Eissele R, Göke R, Willemer S et al (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22:283–291CrossRefPubMed

16.

Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 2:1300–1304CrossRefPubMed

17.

Ørskov C, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV, Holst JJ (1986) Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119:1467–1475CrossRefPubMed

18.

Ørskov C, Jeppesen J, Madsbad S, Holst JJ (1991) Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415–423CrossRefPubMed

19.

D’Alessio D, Thirlby R, Laschansky E, Zebroski H, Ensinck J (1993) Response of tGLP-1 to nutrients in humans. Digestion 54:377–379

20.

Nauck MA, El-Ouaghlidi A, Gabrys B et al (2004) Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 122:209–217CrossRefPubMed

21.

Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43:535–539CrossRefPubMed

22.

Åhren B, Holst JJ (2001) The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes 50:1030–1038CrossRefPubMed

23.

Rask E, Olsson T, Soderberg S et al (2001) Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24:1640–1645CrossRefPubMed

24.

Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609–613CrossRefPubMed

25.

Vollmer K, Holst JJ, Baller B et al (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57:678–687CrossRefPubMed

26.

Reimann F (2006) GLP-1. Diabetes 5(suppl 1):S 78–85

27.

Jang HJ, Kokrashvili Z, Theodorakis MJ et al (2007) Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA 104:15069–15074CrossRefPubMed

28.

Lauffer LM, Iakoubov R, Brubaker PL (2009) GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58:1058–1066CrossRefPubMed

29.

Hirasawa A, Tsumaya K, Awaji T et al (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11:90–94CrossRefPubMed

30.

Zhao X, Cui YM, Zhou Y et al (2008) Exenatide pharmacokinetics in healthy Chinese subjects. Int J Clin Pharmacol Ther 46:459–465PubMed

31.

Gray GM (1970) Carbohydrate digestion and absorption. Gastroenterol 58:96–107

32.

Herrmann-Rinke C, Vöge A, Hess M, Göke B (1995) Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J Endocrinol 147:25–31CrossRefPubMed

33.

Brubaker PL (1991) Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinol 128:3175–3182CrossRef

34.

Rocca AS, Brubaker PL (1999) Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140:1687–1694CrossRefPubMed

35.

Anini Y, Brubaker PL (2003) Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 144:3244–3250CrossRefPubMed

36.

Roberge JN, Brubaker PL (1993) Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133:233–240CrossRefPubMed

37.

Roberge JN, Gronau KA, Brubaker PL (1996) Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. Endocrinology 137:2383–2388CrossRefPubMed

38.

Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307CrossRefPubMed

39.

Fieseler P, Bridenbaugh S, Nustede R et al (1995) Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. Am J Physiol (Endocrinol Metab) 268:E 949–955

40.

Balks HJ, Holst JJ, von zur Mühlen A, Brabant G (1997) Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab 82:786–790CrossRefPubMed

41.

Beglinger S, Drewe J, Schirra J, Göke B, D’Amato M, Beglinger C (2010) Role of fat hydrolysis in regulating glucagon-like peptide-1 secretion. J Clin Endocrinol Metab 95:879–886CrossRefPubMed

42.

Nauck MA, Siemsglüß J, Ørskov C, Holst JJ (1996) Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. Z Gastroenterol 34:159–166PubMed

43.

Hansen L, Lampert S, Mineo H, Holst JJ (2004) Neural regulation of glucagon-like peptide-1 secretion in pigs. Am J Physiol (Endocrinol Metab) 287:E 939–947

44.

Theodorakis MJ, Carlson O, Michopoulos S et al (2006) Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol (Endocrinol Metab) 290:E 550–559

45.

Mortensen K, Petersen LL, Orskov C (2000) Colocalization of GLP-1 and GIP in human and porcine intestine. Ann N Y Acad Sci 921:469–472CrossRefPubMed

46.

Nauck MA, Holst JJ, Willms B, Schmiegel W (1997) Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 105:187–195CrossRefPubMed

47.

Schirra J, Katschinski M, Weidmann C et al (1996) Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97:92–103CrossRefPubMed

48.

Miholic J, Ørskov C, Holst JJ, Kotzerke J, Meyer HJ (1991) Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 36:1361–1370CrossRefPubMed

49.

Fukase N, Takahashi H, Manaka H et al (1992) Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion. Diabetes Res Clin Pract 15:187–195CrossRefPubMed

50.

Patzelt C, Schiltz E (1984) Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences. Proc Natl Acad Sci USA 81:5007–5011CrossRefPubMed

51.

Migoya E, Miller J, Luo W-L et al (2010) Sitagliptin and metformin increase active GLP-1 by complementary mechanisms in treatment-naïve patients with type 2 diabetes. Diabetes 59(suppl 1):A 156

52.

Ranganath LR, Beety LM, Morgan LM, Wright JW, Howland R, Marks V (1996) Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 38:916–919CrossRefPubMed

53.

Hansen L, Hartmann B, Mineo H, Holst JJ (2004) Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Pept 118:11–18CrossRefPubMed

54.

Muscelli E, Mari A, Casolaro A et al (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:1340–1348CrossRefPubMed

55.

Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741–744CrossRefPubMed

56.

Meier JJ, Ritter PR, Jacob A et al (2010) Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans. J Clin Endocrinol Metab 95:4061–4065CrossRefPubMed

57.

Ma J, Stevens JE, Cukier K et al (2009) Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 32:1600–1602CrossRefPubMed

58.

Greenfield JR, Farooqi IS, Keogh JM et al (2009) Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr 89:106–113CrossRefPubMed

59.

Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA (1998) Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet Med 15:485–491CrossRefPubMed

60.

Göke B, Fuder H, Wieckhorst G et al (1995) Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 56:493–501CrossRefPubMed

61.

Lee A, Patrick P, Wishart J, Horowitz M, Morley JE (2002) The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4:329–335CrossRefPubMed

62.

Yasuda N, Inoue T, Nagakura T et al (2002) Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 298:779–784CrossRefPubMed

63.

Burcelin R, Da Costa A, Drucker D, Thorens B (2001) Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50:1720–1728CrossRefPubMed

64.

Kjems LL, Holst JJ, Vølund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380–386CrossRefPubMed

65.

Kolterman OG, Kim DD, Shen L et al (2005) Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am Health Syst Pharm 62:173–181

66.

Elbrønd B, Jakobsen G, Larsen S et al (2002) Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25:1398–1404CrossRefPubMed

67.

Fonseca V, Baron M, Shao Q, Dejager S (2008) Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 40:427–430CrossRefPubMed

68.

Vilsbøll T, Krarup T, Sonne J et al (2003) Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706–2713CrossRefPubMed

69.

Ryskjaer J, Deacon CF, Carr RD et al (2006) Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbA_1c levels, but is not acutely affected by food intake. Eur J Endocrinol 155:485–493CrossRefPubMed

70.

Salinari S, Bertuzzi A, Asnaghi S, Guidone C, Manco M, Mingrone G (2009) First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care 32:375–380CrossRefPubMed

71.

Fukase N, Igarashi M, Takahashi H et al (1993) Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabet Med 10:44–49CrossRefPubMed

Titel: Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
verfasst von: M. A. Nauck
I. Vardarli
C. F. Deacon
J. J. Holst
J. J. Meier
Publikationsdatum: 01.01.2011
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 1/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-010-1896-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Dissociation between fatty liver and insulin resistance: the role of adipose triacylglycerol lipase

Associations between physical fitness and HbA1c in type 2 diabetes mellitus

The beta and alpha cell-specific Znt8-knockout mouse model: new mechanistic insights?

Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus

Erratum to: Expression analysis of loci associated with type 2 diabetes in human tissues